- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of April 16
The Center for Biosimilars® recaps the top 5 biosimilars articles for the week of April 16, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 16.
Number 5: A federal appeals court in Maryland ruled that a recently passed law targeting drug pricing is unconstitutional.
Number 4: The FDA has finalized its guidance on special protocol assessments, which allow product sponsors to meet with the agency to agree on the design and size of clinical trials.
Number 3: A newly published study shows that patients with ankylosing spondylitis who received coaching as part of a patient support program for adalimumab had better clinical outcomes.
Number 2: During a session at the 2018 Community Oncology Conference, hosted by the Community Oncology Alliance, Robert Rifkin, MD, highlighted opportunities and challenges associated with biosimilars.
Number 1: During a panel at the National Policy and Advocacy Summit on Biologics and Biosimilars, panelists discussed key barriers to accessing biologics and other innovative treatments.
Also this week, expert contributor Brian Lehman explained the implications of CMS’ new policy to lower the cost of biosimilars for some Medicare beneficiaries.
Finally, last week, our e-newsletter asked whether you think a 3-year timeline from biosimilar approval to patient switching is too slow.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
